UK markets closed

IO Biotech, Inc. (IOBT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.5400+0.0500 (+3.36%)
As of 10:02AM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 97.50M
Enterprise value -43.20M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)0.73
Enterprise value/revenue N/A
Enterprise value/EBITDA 0.51

Trading information

Stock price history

Beta (5Y monthly) 0.50
52-week change 3-25.37%
S&P500 52-week change 322.38%
52-week high 32.2900
52-week low 30.8160
50-day moving average 31.6025
200-day moving average 31.5419

Share statistics

Avg vol (3-month) 3142.79k
Avg vol (10-day) 365.87k
Shares outstanding 565.88M
Implied shares outstanding 665.88M
Float 825.98M
% held by insiders 12.95%
% held by institutions 181.61%
Shares short (15 Apr 2024) 461.84k
Short ratio (15 Apr 2024) 40.68
Short % of float (15 Apr 2024) 40.26%
Short % of shares outstanding (15 Apr 2024) 40.09%
Shares short (prior month 15 Mar 2024) 481.62k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-37.78%
Return on equity (ttm)-63.29%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -91.23M
Net income avi to common (ttm)-86.08M
Diluted EPS (ttm)-1.9800
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)143.19M
Total cash per share (mrq)2.17
Total debt (mrq)2.49M
Total debt/equity (mrq)1.87%
Current ratio (mrq)9.37
Book value per share (mrq)2.02

Cash flow statement

Operating cash flow (ttm)-71.74M
Levered free cash flow (ttm)-42.19M